Also known as: Samsung Epis Holdings
Samsung Epis Holdings is a South Korean investment holding company focused on biopharmaceutical and biotechnology innovation through subsidiaries such as Samsung Bioepis and Epis NexLab.
Samsung Bioepis plans to start a global Phase 1 trial of SBE303, its first independently developed new drug candidate targeting Nectin-4. Preclinical data showed tolerability up to 40 mg/kg in monkeys.
Samsung Bioepis reached settlement agreements with Regeneron and Bayer for its aflibercept biosimilar OPUVIZ, enabling U.S. launch in January 2027 and staged international rollout beginning early 2026.
